MDxHealth revenue up 16% in Q2, affirms FY26 sales guidance
MDxHealth (NASDAQ: MDXH) reported Q2 2026 revenue of $27.2 million, up 16% year over year and 14% sequentially, and reaffirmed FY26 sales guidance of $110 million to $115 million. Gross profit rose to $17.9 million, but adjusted EBITDA turned negative at -$2.3 million. The company also received a Nasdaq minimum bid notice and raised $20 million via a registered direct placement.
How this was made
The 30-second read
Why it matters
Traders should weigh reaffirmed FY26 revenue guidance and Q2 acceleration against widening operating losses, negative adjusted EBITDA, and the $1.00 bid-price deficiency cure timeline.
Market read
Company-specific catalysts include Q2 financials, guidance reaffirmation, a capital raise for liquidity, and a listing compliance risk that can affect valuation and liquidity.
What to watch
Margin compression is attributed to product mix shift toward tissue-based tests; if mix normalizes, gross margin and operating leverage could improve faster than the market expects.
Background
MDxHealth is transitioning post ExoDx acquisition integration and winding down its Resolve UTI business, while managing Nasdaq listing compliance.
Ticker impact
MDxHealth reported Q2 2026 revenue of $27.2M (+16% YoY), affirmed FY26 sales guidance, and disclosed a Nasdaq bid-price deficiency notice.
Choppy-to-negative bias if the stock is near $1.00 and investors discount delisting risk; upside if liquidity and H2 revenue acceleration appear credible.
The article provides fresh, decision-relevant datapoints: Q2 results with margin/EBITDA deterioration, reaffirmed FY26 revenue guidance above consensus, a $20M registered direct placement, and a Nasdaq compliance cure period through Dec 28, 2026.
Market effects
Could reinforce investor focus on profitability path and integration execution for urology diagnostics companies, not just top-line growth.
Limited direct regional spillover; primarily US-listed small-cap biotech/diagnostics sentiment.
Low; story is company-specific with US Nasdaq listing compliance as the main external driver.
Counterpoint
The Resolve wind-down de-risks a $10.4M contingent liability and the $20M placement extends runway, so the EBITDA swing may be temporary integration noise.
Key entities
- companyMDxHealth
Reported Q2 2026 revenue growth, affirmed FY26 guidance, executed a $20M registered direct placement, and received a Nasdaq minimum bid-price deficiency notice.
- regulator/venueThe Nasdaq Stock Market LLC
Issued the deficiency notification under Nasdaq Listing Rule 5550(a)(2), with a 180-day cure period.
- counterpartyNovitas
Was referenced as the holder of a $10.4M contingent liability removed via the Resolve wind-down.
